文献速递慢性肾脏病

西非HIV阳性患者尿TGF-β1与现患CKD风险

Urinary Transforming Growth Factor-Beta 1 (uTGF-β1) and Prevalent CKD Risk in HIV-Positive Patients in West Africa.
PubMed 文献 · Kidney Int Rep · 2019-07-27

本研究纳入西非无高血压、糖尿病及肝炎的HIV阳性患者,比较合并CKD(n=114)与无CKD(n=194)者尿TGF-β1-肌酐比值(uTGF-β1Cr)。结果显示HIV+CKD+组uTGF-β1Cr中位数显著更高(4.85 vs 2.95 ng/mmol,P=0.001),且随CKD分期加重逐渐降低(P=0.04),蛋白尿可解释uTGF-β1Cr与eGFR的关联。

要点

  • HIV合并CKD患者尿TGF-β1Cr显著高于无CKD者。
  • uTGF-β1Cr随CKD分期加重而逐渐降低。
  • 蛋白尿可解释uTGF-β1Cr与eGFR变化的关联。

核心结论

  • HIV+CKD+患者尿TGF-β1水平更高,尤其在CKD早期,且明显与蛋白尿水平相关。

研究设计与样本

  • 横断面研究,纳入HIV阳性无CKD者194例和合并CKD者114例,均无高血压、糖尿病及乙型或丙型肝炎。

主要发现

  • HIV+CKD+组uTGF-β1Cr中位数为4.85 ng/mmol(25th-75th百分位1.96-12.35),显著高于HIV+CKD-组的2.95(1.02-5.84),P=0.001。
  • HIV+CKD+组uTGF-β1Cr与年龄(P=0.02)、eGFR(P=0.001)及uPCR(P<0.001)显著相关。
  • HIV+CKD+组中uTGF-β1Cr中位水平随CKD严重程度逐渐降低(P=0.04)。
  • 控制潜在混杂因素后,HIV+CKD+患者uTGF-β1Cr仍显著更高。
  • 以eGFR为因变量时,蛋白尿解释了与uTGF-β1Cr水平相关的变化。

临床怎么用

  • 在HIV阳性合并CKD患者中,尿TGF-β1可能作为反映蛋白尿相关肾损伤的无创标志物,尤其在CKD早期。

局限性

  • 研究未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study investigated the association of urinary transforming growth factor-β1 (uTGF-β1) with prevalent chronic kidney disease (CKD) in the HIV-infected population. METHODS: HIV-positive patients without CKD (HIV+CKD-, n = 194) and 114 with CKD (HIV+CKD+) who did not have hypertension, diabetes mellitus, or hepatitis B or C, had their urinary protein-creatinine ratio (uPCR), serum transforming growth factor (TGF)-β1, and uTGF-β1 measured. uTGF-β1-creatinine ratios (uTGF-β1Cr) were calculated. Spearman correlation was used to determine the association between uTGF-β1Cr and various attributes, and the Cuzick trend test was used to assess the presence of a linear trend in median uTGF-β1Cr levels across the stages of CKD. Multivariable robust linear regression models were used to assess independent association with variability in uTGF-β1Cr and estimated glomerular filtration rate (eGFR) levels. RESULTS: The age of the participants was 38.3 ± 10.3 years with 73.4% women. The median uTGF-β1Cr was higher among HIV+CKD+ (4.85 ng/mmol [25th-75th percentile 1.96-12.35] vs. 2.95 [1.02-5.84]; P = 0.001]). There was significant correlation between uTGF-β1Cr and age (P = 0.02), eGFR (P = 0.001), and uPCR (P < 0.001) in the HIV+CKD+ group. Among the HIV+CKD+ patients, there was gradual reduction in the median level of uTGF-β1Cr with CKD severity (P = 0.04). HIV+CKD+ patients had significantly higher levels of uTGF-β1Cr after controlling for potential confounders. Using eGFR as dependent variable, proteinuria explained the changes associated with uTGF-β1Cr levels. CONCLUSION: HIV+CKD+ patients express higher levels of uTGF-β1 especially in the early stages of CKD apparently related to proteinuria levels.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ekrikpo UE, Okuku CN, Ajayi SO, et al. Urinary Transforming Growth Factor-Beta 1 (uTGF-β1) and Prevalent CKD Risk in HIV-Positive Patients in West Africa. Kidney Int Rep. 2019. PMID: 31844806. doi:10.1016/j.ekir.2019.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。